Home > Result Summaries: Compounds > Human Papillomavirus Types 16 and 18 Vaccine > Result Summary for 106001

Result Summary for 106001

Result Summary

Protocol ID:	106001
Clinical Study ID:	106001
Official Title:	A phase III, double-blind, randomized, controlled study to evaluate immunogenicity & safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine, administered intramuscularly (0, 1, 6 month schedule) in healthy females aged 18 – 35 years
Phase:	phase 3
Study Indications or Diseases:	Human Papillomavirus (HPV)
Generic Name:	Human Papillomavirus Types 16 and 18 Vaccine
Trade/Product Name:	Cervarix
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Verstraeten T et al. (2008) Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 26(51):6630–6638. Ngan HY et al. (2010) Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med J. 16(3): 171-179.